Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial

Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial

Apart from all the gloominess, the COVID-19 Pandemic has a silver lining of bringing a renaissance as Ayurveda and integrated medicine are becoming a choice for acute as well as infective diseases. Here we report outcomes of a preliminary work, the randomized controlled trial (CTRI/2021/02/031256) o...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Sameer Jamadagni, Prasad Pandkar, Tushar Saundankar, Girish Shirke, Shailesh Malekar, V.G. Vaidya
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Elsevier 2022-07-01
Saila:Journal of Ayurveda and Integrative Medicine
Gaiak:
Ayurveda
COVID-19
Madhav rasayan plus
Clinical trial
Integrative medicine
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S0975947622000493

Antzeko izenburuak

Antzeko izenburuak